AbCellera Biologics Inc. (ABCL): who owns it and who trades it
As of Nov 16, 2026, ABCL insiders reported 11 purchases worth $3.5M in the last 12 months. The largest buyer was Thermopylae Holdings Ltd. (10% owner), with $1.4M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling AbCellera Biologics
From the latest filingsOverall: more buying than selling. Insiders mostly bought. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ABCL
151 funds and institutions reported ABCL shares worth $909M at the end of Q2 2026, about 38% of the company. The largest holder is Baker Bros. Advisors LP with 10.8%.
Funds and institutions (13F) 38%Everyone else 62%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 33.01M | 10.81% | $259M | +9% |
| Capital World Investors | 13.59M | 4.45% | $107M | +2% |
| Two Sigma Investments, LP | 10.44M | 3.42% | $81.9M | -1% |
| TD Waterhouse Canada Inc. | 9.57M | 3.13% | $72.6M | No change |
| Bank of America Corp | 6.14M | 2.01% | $48.2M | +105% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 4.32M | 1.41% | $33.9M | -43% |
| ArrowMark Colorado Holdings LLC | 4.11M | 1.34% | $32.2M | No change |
| BlackRock, Inc. | 3.81M | 1.25% | $29.9M | -6% |
| Driehaus Capital Management LLC | 2.86M | 0.94% | $22.5M | -29% |
| Tudor Investment Corp Et Al | 2.06M | 0.68% | $16.2M | -9% |
| Marshall Wace, LLP | 1.90M | 0.62% | $14.9M | +429% |
| UBS Group AG | 1.87M | 0.61% | $14.7M | -56% |
| Morgan Stanley | 1.67M | 0.55% | $13.1M | -25% |
| T. Rowe Price Associates | 1.59M | 0.52% | $12.5M | – |
| Citadel Advisors LLC | 1.59M | 0.52% | $12.5M | +17% |
| National Bank of Canada | 1.23M | 0.40% | $9.7M | – |
| Arrowstreet Capital, Limited Partnership | 1.04M | 0.34% | $8.2M | – |
| Renaissance Technologies LLC | 990,929 | 0.32% | $7.8M | -34% |
| Counterpoint Mutual Funds LLC | 971,643 | 0.32% | $7.6M | – |
| State Street Corp | 731,362 | 0.24% | $5.7M | +0% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ABCL insiders reported $3.5M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Andrew Booth | CFO | Purchase | 8,600 | $11.33 | $97.4K | Form 4 |
| Nov 12, 2026 | Thermopylae Holdings Ltd. | 10% owner | Purchase | 60,565 | $11.54 | $699K | Form 4 |
| Aug 24, 2026 | Michael R Hayden | Director | Purchase | 53,613 | $10.64 | $570K | Form 4 |
| Aug 18, 2026 | John S. Montalbano | Director | Purchase | 10,000 | $11.03 | $110K | Form 4 |
| Aug 14, 2026 | Andrew Booth | CFO | Purchase | 37,200 | $10.32 | $384K | Form 4 |
| Aug 12, 2026 | Michael R Hayden | Director | Purchase | 46,387 | $10.37 | $481K | Form 4 |
| May 14, 2026 | John S. Montalbano | Director | Purchase | 20,000 | $4.77 | $95.4K | Form 4 |
| Feb 27, 2026 | Thermopylae Holdings Ltd. | 10% owner | Purchase | 38,000 | $3.44 | $131K | Form 4 |
| Feb 27, 2026 | Andrew Booth | CFO | Purchase | 42,600 | $3.42 | $146K | Form 4 |
| Feb 26, 2026 | Thermopylae Holdings Ltd. | 10% owner | Purchase | 177,457 | $3.27 | $580K | Form 4 |
| Nov 26, 2025 | John S. Montalbano | Director | Purchase | 50,000 | $3.57 | $178K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Thermopylae Holdings Ltd. | 10% owner | $1.4M | – | Nov 12, 2026 |
| Michael R Hayden | Director | $1.1M | – | Aug 24, 2026 |
| Andrew Booth | Chief Financial Officer | $627K | – | Nov 13, 2026 |
| John S. Montalbano | Director | $384K | – | Aug 18, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ABCL short interest
Moderate short interest. 9.5% of ABCL shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 32%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 29.02M ABCL shares were sold short, 9.5% of the shares outstanding, down 6.2% from the report before. At the average daily volume of 3.42M shares, buying them all back would take about 8.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 29.02M | 9.47% | -6% | 3.42M | 8.5 |
| Oct 15, 2026 | 30.93M | 10.09% | -5% | 5.49M | 5.6 |
| Sep 30, 2026 | 32.50M | 10.60% | -4% | 5.43M | 6.0 |
| Sep 15, 2026 | 33.93M | 11.07% | -2% | 3.52M | 9.6 |
| Aug 31, 2026 | 34.75M | 11.33% | -16% | 6.71M | 5.2 |
| Aug 14, 2026 | 41.34M | 13.48% | -14% | 13.58M | 3.0 |
| Jul 31, 2026 | 48.32M | 15.82% | +7% | 5.00M | 9.7 |
| Jul 15, 2026 | 45.11M | 14.77% | -7% | 6.47M | 7.0 |
| Jun 30, 2026 | 48.56M | 15.90% | +8% | 9.11M | 5.3 |
| Jun 15, 2026 | 44.91M | 14.71% | -5% | 6.29M | 7.1 |
| May 29, 2026 | 47.12M | 15.43% | +10% | 8.45M | 5.6 |
| May 15, 2026 | 42.95M | 14.06% | -3% | 10.13M | 4.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
AbCellera Biologics company events
AbCellera Biologics filed 15 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, auditor). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Aug 13, 2026AgreementAbCellera Biologics Inc. entered into an underwriting agreement with Jefferies LLC and J.P. Morgan Securities LLC as the representatives of the several underwriters relating to an underwritten public offering of (a) 17,435,897 shares of the Company’s common shares, no par value per share at a price… Filing
- Aug 10, 2026AnnouncementShared information with investors. Filing
- Aug 7, 2026AnnouncementAbCellera Biologics Inc. issued a press release announcing it will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause on Monday, August 10, 2026 and hold an investor conference call at 4:30 a.m. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jul 29, 2026AnnouncementAbCellera Biologics Inc. issued a press release announcing a collaboration with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Filing
- Jul 6, 2026LeadershipThe Board of Directors of AbCellera Biologics Inc. appointed Lynn Seely, M.D as a new Class III director. Filing
- Jun 17, 2026AnnouncementAbCellera Biologics Inc. issued a press release announcing a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- Jun 5, 2026LeadershipThe Board of Directors of AbCellera Biologics Inc. appointed Victor Sandor as a new director. Filing
- May 11, 2026ResultsReleased financial results. Filing
- Feb 24, 2026ResultsReleased financial results. Filing
- Jan 14, 2026AnnouncementShared information with investors. Filing
- Dec 18, 2025AnnouncementShared information with investors. Filing
- Nov 28, 2025AuditorThe Audit Committee of the Board of Directors of AbCellera Biologics Inc. approved the dismissal of KPMG LLP as the Company's independent registered public accounting firm, effective following the completion of KPMG's audit of the Company's consolidated financial statements for the fiscal year… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
AbCellera Biologics financials
Famous investors that hold ABCL
6 of the 50 well-known investors we track reported holding ABCL in their latest 13F filing. The largest position is Israel Englander's, worth $29.7M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 2.04M | $29.7M | 0.0% | +293% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 913,226 | $13.3M | 0.1% | -56% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 795,856 | $11.6M | 0.0% | -50% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 462,426 | $6.7M | 0.0% | -53% |
| George Soros · Soros Fund Management | Q3 2026 | 150,000 | $2.2M | 0.0% | New |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 136,181 | $2M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ABCL in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | Carl L.G. Hansen | 13G/A | 19.7% |
| Nov 13, 2026 | Carl L.G. Hansen | 13G/A | 19.7% |
Questions about AbCellera Biologics Inc. (ABCL) stock
Who owns the most ABCL stock?
The largest reported owner of AbCellera Biologics Inc. (ABCL) is Baker Bros. Advisors LP, with 10.8% of the company. In total, 151 funds and institutions reported holding ABCL at the end of Q2 2026, together about 38% of the shares. See the largest owners.
Are ABCL insiders buying or selling?
In the last 12 months, ABCL insiders reported 11 open-market purchases worth $3.5M and no sales. The latest trade was on Nov 13, 2026. See every trade.
What is the short interest in ABCL?
As of Oct 30, 2026, 29.02M ABCL shares were sold short, 9.5% of the shares outstanding, down 6.2% from the report before. At the average daily volume of 3.42M shares, buying them all back would take about 8.5 trading days (days to cover). See the history.
Which famous investors hold ABCL?
6 of the 50 well-known investors we track reported ABCL in their latest 13F filing, including Israel Englander, Paul Tudor Jones, Ken Griffin. The largest position is worth $29.7M. See all holders.
Executive pay
AbCellera Biologics's chief executive was paid a total of $6.3M for the year ended Dec 31, 2025, down 24% from $8.2M the year before. In the last 12 months, AbCellera Biologics's executives and directors bought $2.1M of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.